tRNA1Arg(UCU) levels control lineage shifts and drug resistance in prostate cancer
Researchers identified a specific tRNA molecule that regulates cell lineage transitions and therapy resistance in prostate cancer models.
Small RNA sequencing reveals new regulator
Scientists performed unbiased small RNA sequencing to find factors controlling lineage plasticity. They identified tRNA1Arg(UCU) as a key molecule that regulates these transitions. This discovery highlights a previously unrecognized regulatory axis involving non-canonical tRNA-specific gene regulation.
Proteins bind genomic locus directly
The study found TARDBP and ZSCAN29 act as DNA-binding proteins at the tRNA1Arg(UCU) locus. These proteins engage the genomic site to control expression levels of the molecule. This mechanism links codon biology directly to lineage dependence in cancer cells.
Patient data shows survival impact
Analysis of patient samples showed tRNA1Arg(UCU) is downregulated in neuroendocrine prostate cancer cases. The loss of this molecule correlates with accelerated metastasis and poor survival outcomes. Restoring sensitivity to androgen receptor therapies depends on tuning these dosage levels.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.